Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21509919 | 1.00 | TSHR (0.43) | TSHRNPSR1HPGDSMN1; SMN2MBTPS1 | |
| SCHEMBL25646519 | 1.00 | TSHR (0.43) | TSHRNPSR1HPGDSMN1; SMN2MBTPS1 | |
| SCHEMBL23135886 | 0.84 | CA12 (0.47) | TSHRHPGDSMN1; SMN2CA12CA14 | |
| SCHEMBL5711380 | 0.84 | MBTPS1 (0.50) | TSHRNPSR1HPGDSMN1; SMN2MBTPS1 | |
| SCHEMBL10881354 | 0.79 | TSHR (0.40) | TSHRHPGDSMN1; SMN2ACACBALDH1A1 | |
| SCHEMBL25646522 | 0.79 | TSHR (0.46) | TSHRNPSR1HPGDSMN1; SMN2ACACB | |
| SCHEMBL13748651 | 0.78 | NPC1 (0.42) | TSHRNPSR1ALDH1A1POLB | |
| SCHEMBL15996559 | 0.77 | CYP2C9 (0.45) | NPSR1SMN1; SMN2ALDH1A1PSMB5 | |
| SCHEMBL22267166 | 0.77 | CYP2C9 (0.45) | NPSR1SMN1; SMN2ALDH1A1PSMB5 | |
| SCHEMBL13932943 | 0.77 | CYP2C9 (0.45) | NPSR1SMN1; SMN2ALDH1A1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | SCHERING CORPORATION | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | HAVCR2, ELOC, ZC3HAV1 | TSHR 3711/4885NPSR1 2897/4885HPGD 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.